Improving the safety of radiotherapy treatment processes via incident-driven FMEA feedback loops.

error rates failure mode and effects analysis (FMEA) incident reporting system (IRS) radiotherapy risk assessment

Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
05 Aug 2024
Historique:
revised: 22 05 2024
received: 20 03 2024
accepted: 26 06 2024
medline: 5 8 2024
pubmed: 5 8 2024
entrez: 5 8 2024
Statut: aheadofprint

Résumé

Failure mode and effects analysis (FMEA) is a valuable tool for radiotherapy risk assessment, yet its outputs might be unreliable due to failures not being identified or due to a lack of accurate error rates. A novel incident reporting system (IRS) linked to an FMEA database was tested and evaluated. The study investigated whether the system was suitable for validating a previously performed analysis and whether it could provide accurate error rates to support the expert occurrence ratings of previously identified failure modes. Twenty-three pre-identified failure modes of our external beam radiotherapy process, covering the process steps from patient admission to treatment delivery, were proffered on dedicated FMEA feedback and incident reporting terminals generated by the IRS. The clinical setting involved a computed tomography scanner, dosimetry, and five linacs. Incoming reports were used as basis to identify additional failure modes or confirm initial ones. The Kruskal-Wallis H test was applied to compare the risk priorities of the retrospective and prospective failure modes. Wald's sequential probability ratio test was used to investigate the correctness of the experts' occurrence ratings by means of the number of incoming reports. Over a 15-month period, 304 reports were submitted. There were 0.005 (confidence interval [CI], 0.0014-0.0082) reported incidents per imaging study and 0.0006 (CI, 0.0003-0.0009) reported incidents per treatment fraction. Sixteen additional failure modes could be identified, and their risk priorities did not differ from those of the initial failure modes (p = 0.954). One failure mode occurrence rating could be increased, whereas the other 22 occurrence ratings could not be disproved. Our approach is suitable for validating FMEAs and deducing additional failure modes on a continual basis. Accurate error rates can only be provided if a sufficient number of reports is available.

Sections du résumé

BACKGROUND BACKGROUND
Failure mode and effects analysis (FMEA) is a valuable tool for radiotherapy risk assessment, yet its outputs might be unreliable due to failures not being identified or due to a lack of accurate error rates.
PURPOSE OBJECTIVE
A novel incident reporting system (IRS) linked to an FMEA database was tested and evaluated. The study investigated whether the system was suitable for validating a previously performed analysis and whether it could provide accurate error rates to support the expert occurrence ratings of previously identified failure modes.
METHODS METHODS
Twenty-three pre-identified failure modes of our external beam radiotherapy process, covering the process steps from patient admission to treatment delivery, were proffered on dedicated FMEA feedback and incident reporting terminals generated by the IRS. The clinical setting involved a computed tomography scanner, dosimetry, and five linacs. Incoming reports were used as basis to identify additional failure modes or confirm initial ones. The Kruskal-Wallis H test was applied to compare the risk priorities of the retrospective and prospective failure modes. Wald's sequential probability ratio test was used to investigate the correctness of the experts' occurrence ratings by means of the number of incoming reports.
RESULTS RESULTS
Over a 15-month period, 304 reports were submitted. There were 0.005 (confidence interval [CI], 0.0014-0.0082) reported incidents per imaging study and 0.0006 (CI, 0.0003-0.0009) reported incidents per treatment fraction. Sixteen additional failure modes could be identified, and their risk priorities did not differ from those of the initial failure modes (p = 0.954). One failure mode occurrence rating could be increased, whereas the other 22 occurrence ratings could not be disproved.
CONCLUSIONS CONCLUSIONS
Our approach is suitable for validating FMEAs and deducing additional failure modes on a continual basis. Accurate error rates can only be provided if a sufficient number of reports is available.

Identifiants

pubmed: 39101683
doi: 10.1002/acm2.14455
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14455

Subventions

Organisme : Bavarian Ministry of Economic Affairs, Regional Development, and Energy
ID : 07 03/686 68/288/21/7/22/8/23/9/24
Organisme : Bavarian Ministry of Economic Affairs, Regional Development, and Energy
ID : 07 03/686 68/287/21/4/22/5/23/6/24

Informations de copyright

© 2024 The Author(s). Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Références

Liu HC, Zhang LJ, Ping YJ, Wang L. Failure mode and effects analysis for proactive healthcare risk evaluation: a systematic literature review. J Eval Clin Pract. 2020;26(4):1320‐1337. doi:10.1111/jep.13317
Bright M, Foster RD, Hampton CJ, Ruiz J, Moeller B. Failure modes and effects analysis for surface‐guided DIBH breast radiotherapy. J Appl Clin Med Phys. 2022;23(4):e13541. doi:10.1002/acm2.13541
Rassiah P, Su FF, Huang YJ, et al. Using failure mode and effects analysis (FMEA) to generate an initial plan check checklist for improved safety in radiation treatment. J Appl Clin Med Phys. 2020;21(8):83‐91. doi:10.1002/acm2.12918
Gilmore MDF, Rowbottom CG. Evaluation of failure modes and effect analysis for routine risk assessment of lung radiotherapy at a UK center. J Appl Clin Med Phys. 2021;22(5):36‐47. doi:10.1002/acm2.13238
Gray T, Antolak A, Ahmed S, et al. Implementing failure mode and effect analysis to improve the safety of volumetric modulated arc therapy for total body irradiation. Med Phys. 2023;50(7):4092‐4104. doi:10.1002/mp.16466
Esposito M, Mancosu P, Bruschi A, et al. Correction to: the role of EPID in vivo dosimetry in the risk management of stereotactic lung treatments. Strahlenther Onkol. 2024;200(1):106. doi:10.1007/s00066‐023‐02168‐5
Baehr A, Hummel D, Gauer T, et al. Risk management patterns in radiation oncology‐results of a national survey within the framework of the Patient Safety in German Radiation Oncology (PaSaGeRO) project. Strahlentherapie Und Onkologie. 2022;199(4):350‐359. doi:10.1007/s00066‐022‐01984‐5
Huq MS, Fraass BA, Dunscombe PB, et al. The report of Task Group 100 of the AAPM: application of risk analysis methods to radiation therapy quality management. Med Phys. 2016;43(7):4209. doi:10.1118/1.4947547
Commission E. RADIATION PROTECTION N° 181. General guidelines on risk management in external beam radiotherapy; 2015.
Ashley L, Armitage G, Neary M, Hollingsworth G. A practical guide to failure mode and effects analysis in health care: making the most of the team and its meetings. Jt Comm J Qual Patient Saf. 2010;36(8):351‐358. doi:10.1016/s1553‐7250(10)36053‐3
Wegener S, Exner F, Weick S, et al. Prospective risk analysis of the online‐adaptive artificial intelligence‐driven workflow using the Ethos treatment system. Z Med Phys. 2022. doi:10.1016/j.zemedi.2022.11.004
Shebl NA, Franklin BD, Barber N. Failure mode and effects analysis outputs: are they valid? BMC Health Serv Res. 2012;12:150. doi:10.1186/1472‐6963‐12‐150
Yang F, Cao N, Young L, et al. Validating FMEA output against incident learning data: a study in stereotactic body radiation therapy. Med Phys. 2015;42(6):2777‐2785. doi:10.1118/1.4919440
Kornek D, Menichelli D, Leske J, et al. Development and clinical implementation of a digital system for risk assessments for radiation therapy. Z Med Phys. 2023. doi:10.1016/j.zemedi.2023.08.003
DIN EN 15224:2017‐05. Quality management systems—EN ISO 9001:2015 for healthcare; German version EN 15224:2016. Berlin: Beuth Verlag; 2017. doi:10.31030/2581525
Lohmann D, Lang‐Welzenbach M, Feldberger L, et al. Risk analysis for radiotherapy at the Universitatsklinikum Erlangen. Z Med Phys. 2022;32(3):273‐282. doi:10.1016/j.zemedi.2021.11.002
IEC 60812:2018. Failure modes and effects analysis (FMEA and FMECA). Berlin: Beuth Verlag; 2018.
Wald A. Sequential tests of statistical hypotheses. The Ann Math Stat. 1945;16(2): 117‐186, 70.
Kessels‐Habraken M, Van der Schaaf T, De Jonge J, Rutte C, Kerkvliet K. Integration of prospective and retrospective methods for risk analysis in hospitals. Int J Qual Health Care. 2009;21(6):427‐432. doi:10.1093/intqhc/mzp043
Mutic S, Brame RS, Oddiraju S, et al. Event (error and near‐miss) reporting and learning system for process improvement in radiation oncology. Med Phys. 2010;37(9):5027‐5036. doi:10.1118/1.3471377
Smith S, Wallis A, King O, et al. Quality management in radiation therapy: a 15 year review of incident reporting in two integrated cancer centres. Tech Innov Patient Support Radiat Oncol. 2020;14:15‐20. doi:10.1016/j.tipsro.2020.02.001
Ibanez‐Rosello B, Bautista JA, Bonaque J, et al. Failure modes and effects analysis of total skin electron irradiation technique. Clin Transl Oncol. 2018;20(3):330‐365. doi:10.1007/s12094‐017‐1721‐3
Paradis KC, Naheedy KW, Matuszak MM, Kashani R, Burger P, Moran JM. The fusion of incident learning and failure mode and effects analysis for data‐driven patient safety improvements. Pract Radiat Oncol. 2021;11(1):e106‐e113. doi:10.1016/j.prro.2020.02.015

Auteurs

Dominik Kornek (D)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Michael Lotter (M)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Juliane Szkitsak (J)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Christopher Dürrbeck (C)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Andre Karius (A)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Oliver J Ott (OJ)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Carolin Brandl (C)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Christoph Bert (C)

Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

Classifications MeSH